CureVac Delisted Following BioNTech Acquisition Completion

The chapter for CureVac as an independent publicly traded company has officially closed. The biotech firm’s shares have been removed from the Nasdaq exchange and trading has ceased, marking its full absorption into rival BioNTech. The Tübingen-based company, once a beacon of hope in the sector, has now been integrated into its competitor’s corporate structure.

Leadership and Operational Integration

A complete leadership overhaul accompanied the change in ownership. CureVac’s former executive board resigned en masse. The company’s operations are now directed by BioNTech’s leadership, including CEO Ugur Sahin and COO Sierk Poetting. The primary operational focus is on integration: BioNTech is absorbing CureVac’s research facilities and production capacities in Tübingen. This move is designed to significantly enhance BioNTech’s own expertise in mRNA design and manufacturing.

This acquisition finalizes a major consolidation within the German biotechnology landscape. By merging the two most prominent mRNA specialists, resources are now concentrated under the BioNTech umbrella. The deal substantially strengthens BioNTech’s market position, particularly through the acquisition of CureVac’s oncology pipeline.

Should investors sell immediately? Or is it worth buying CureVac?

Finalizing the Takeover and Shareholder Impact

BioNTech finalized its acquisition of CureVac on January 6, 2026. The inevitable consequence for the stock listing followed just ten days later. As of January 16, 2026, CureVac equity is no longer tradable on the US-based Nasdaq technology exchange. The company now operates as a wholly-owned subsidiary of the Mainz-based firm. Corresponding deregistration procedures were initiated with the U.S. Securities and Exchange Commission (SEC) to terminate all ongoing reporting obligations.

Shareholders had previously delivered a clear verdict on the deal. By the close of the exchange offer period in December 2025, approximately 195.3 million CureVac shares had been tendered. This figure represented about 86.75% of the outstanding stock. The remaining shares were subsequently acquired through a legal squeeze-out procedure.

For former equity holders, the transaction’s conclusion presented a definitive outcome. Those who accepted the exchange offer received American Depositary Shares (ADS) of BioNTech in return. Investors who retained their CureVac shares received a cash settlement, subject to tax deductions under Dutch law.